P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA

• K Kuo,
• D Layton,
• H Al-Samkari,
• A Kattamis,
• S Sheth,
• A Taher,
• V Viprakasit,
• C Chamberlain,
• L Czapla,
• S Gheuens,
• M Lynch,
• B Tong,
• K Uhlig,
• M Cappellini

Affiliations

K Kuo

1 Division of Hematology, University of Toronto, Toronto, ON, CANADA

D Layton

2 Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM

H Al-Samkari

3 Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, UNITED STATES

A Kattamis

4 First Department of Pediatrics, National and Kapodistrian University of Athens BR, Athens, GREECE

S Sheth

5 Weill Cornell Medical College, New York, NY, UNITED STATES

A Taher

6 American University of Beirut, Beirut, LEBANON

V Viprakasit

7 Siriraj-Thalassemia Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, THAILAND

C Chamberlain

8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

L Czapla

8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

S Gheuens

8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

M Lynch

8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

B Tong

8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

K Uhlig

8 Agios Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES

M Cappellini

9 University of Milan, Milan, ITALY